Hikal Ltd. Q1 FY27 Results: Net Loss of ₹7.5 Crore, Revenue at ₹402.8 Crore
Hikal Limited reported a consolidated net loss of ₹7.4 crore for Q1 FY27, with revenue at ₹402.8 crore. Standalone net loss was ₹7.5 crore. The trading window reopens on August 09, 2026. An ongoing environmental law matter and a USFDA warning letter continue to be noted.
The net loss for the quarter, while an improvement from the previous year's loss, indicates ongoing financial challenges. The revenue growth is a positive sign, but the persistence of regulatory issues and the impact on the Pharma segment warrant a medium impact assessment.
The company reported a net loss for the quarter, which is a negative indicator. However, revenue saw an increase compared to the previous year, and the auditors provided an unmodified review conclusion. The ongoing legal and regulatory issues are noted as potential risks.
Hikal Limited announced its unaudited financial results for the quarter ended June 30, 2026, during its Board Meeting held on August 06, 2026. The company reported a consolidated net loss of ₹7.4 crore for the quarter, compared to a net loss of ₹22.4 crore in the same period last year. The total revenue from operations for the quarter stood at ₹402.8 crore, an increase from ₹380.4 crore in the corresponding quarter of the previous fiscal year.
Standalone revenue from operations was ₹402.8 crore for the quarter ended June 30, 2026. The company incurred a standalone net loss of ₹7.5 crore for the quarter. The Board Meeting commenced at 11:00 a.m. and concluded at 02:34 p.m.
The trading window for trading in securities of the Company by Designated Persons, which was closed from July 01, 2026, will re-open on August 09, 2026. The special closure of the trading window will continue to remain closed for Directors, KMPs and specified Senior Management Personnel until informed otherwise.
The company's auditors, S R B C & CO LLP, have provided an unmodified review conclusion on both the standalone and consolidated financial results. The auditors noted an ongoing matter regarding alleged non-compliance with environmental laws, which is pending before the Supreme Court of India. Additionally, a USFDA warning letter issued in August 2025 relating to the Jigani facility has impacted sales for the Pharma Segment.
What to do with a filing like this
Hikal Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hikal Limited. Read the original for the full detail.